Amarin (Amarin) Total Liabilities : $279.6 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Amarin Total Liabilities?

Amarin's Total Liabilities for the quarter that ended in Dec. 2023 was $279.6 Mil.

Amarin's quarterly Total Liabilities declined from Jun. 2023 ($290.89 Mil) to Sep. 2023 ($285.88 Mil) and declined from Sep. 2023 ($285.88 Mil) to Dec. 2023 ($279.59 Mil).

Amarin's annual Total Liabilities declined from Dec. 2021 ($400.97 Mil) to Dec. 2022 ($290.85 Mil) and declined from Dec. 2022 ($290.85 Mil) to Dec. 2023 ($279.59 Mil).

Amarin Total Liabilities Historical Data

The historical data trend for Amarin's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Total Liabilities Chart

Amarin Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

273.95

338.52

400.97

290.85

279.59

Amarin Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															290.85	275.40	290.89	285.88	279.59

Amarin Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amarin's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	259.277	+	(8.737	+	9.064
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.509	+	0)
	=	279.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	831.684	-	552.097
	=	279.6

Amarin's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	259.277	+	(8.737	+	9.064
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.509	+	0)
	=	279.6

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	831.684	-	552.097
	=	279.6

Amarin Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amarin's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amarin (Amarin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EH3A:Germany

Address

112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28

Website

https://amarincorp.com

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.

Executives

Steven B Ketchum	officer: Chief Scientific Officer	2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt	director, officer: See Remarks	C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn	director	204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio	director	488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly	officer: SVP and CFO	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg	officer: EVP, President US	C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail	director, officer: President and CEO	C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart	director	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3